Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

1O86

Crystal Structure of Human Angiotensin Converting Enzyme in complex with lisinopril.

Summary for 1O86
Entry DOI10.2210/pdb1o86/pdb
Related1O8A
Related PRD IDPRD_000560
DescriptorANGIOTENSIN CONVERTING ENZYME, GLYCINE, ZINC ION, ... (6 entities in total)
Functional Keywordsmetalloprotease, peptidyl dipeptidase, type-i membrane-anchored protein, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceHOMO SAPIENS (HUMAN)
Total number of polymer chains1
Total formula weight68685.79
Authors
Natesh, R.,Schwager, S.L.U.,Sturrock, E.D.,Acharya, K.R. (deposition date: 2002-11-25, release date: 2003-02-07, Last modification date: 2024-10-16)
Primary citationNatesh, R.,Schwager, S.L.U.,Sturrock, E.D.,Acharya, K.R.
Crystal Structure of the Human Angiotensin-Converting Enzyme-Lisinopril Complex
Nature, 421:551-, 2003
Cited by
PubMed Abstract: Angiotensin-converting enzyme (ACE) has a critical role in cardiovascular function by cleaving the carboxy terminal His-Leu dipeptide from angiotensin I to produce a potent vasopressor octapeptide, angiotensin II. Inhibitors of ACE are a first line of therapy for hypertension, heart failure, myocardial infarction and diabetic nephropathy. Notably, these inhibitors were developed without knowledge of the structure of human ACE, but were instead designed on the basis of an assumed mechanistic homology with carboxypeptidase A. Here we present the X-ray structure of human testicular ACE and its complex with one of the most widely used inhibitors, lisinopril (N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; also known as Prinivil or Zestril), at 2.0 A resolution. Analysis of the three-dimensional structure of ACE shows that it bears little similarity to that of carboxypeptidase A, but instead resembles neurolysin and Pyrococcus furiosus carboxypeptidase--zinc metallopeptidases with no detectable sequence similarity to ACE. The structure provides an opportunity to design domain-selective ACE inhibitors that may exhibit new pharmacological profiles.
PubMed: 12540854
DOI: 10.1038/NATURE01370
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

226707

数据于2024-10-30公开中

PDB statisticsPDBj update infoContact PDBjnumon